(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Nuvalent's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,588,423,603, with the lowest NUVL revenue forecast at $52,299,394, and the highest NUVL revenue forecast at $5,038,575,350. On average, 18 Wall Street analysts forecast NUVL's revenue for 2027 to be $12,933,070,464, with the lowest NUVL revenue forecast at $2,814,476,938, and the highest NUVL revenue forecast at $24,124,088,037.
In 2028, NUVL is forecast to generate $36,317,004,143 in revenue, with the lowest revenue forecast at $13,830,271,327 and the highest revenue forecast at $80,195,506,645.